Assembly Biosciences Inc - Understand $asmb stock

$ASMB Market Cap: $115.3 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$21.48M

TTM

Gross Margin

Net Earnings

-$45.61M

TTM

Current Assets

$112.9M

Q2 2024

Current Liabilities

$41.27M

Q2 2024

Current Ratio

273.61%

Q2 2024

Total Assets

$115.3M

Q2 2024

Total Liabilities

$80.64M

Q2 2024

Book Value

$34.68M

Q2 2024

Cash

$19.21M

Q2 2024

P/E

-2.528

Sep 18, 2024 EST

Free Cash Flow

$24.10M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue	$7.163M	$0.00	$6.254M	$79.11M	$15.96M	$14.80M	$50.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	-92.09%	395.58%	7.83%	-70.39%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue	$7.163M	$0.00	$6.254M	$79.11M	$15.96M	$14.80M	$50.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Selling, General & Admin	$22.91M	$23.91M	$28.50M	$36.86M	$32.92M	$34.80M	$17.02M	$12.19M	$11.30M	$13.24M	$19.60M	$5.340M	$2.880M	$620.0K	$400.0K	$1.190M
YoY Change	-4.17%	-16.13%	-22.67%	11.97%	-5.4%	104.47%	39.62%	7.88%	-14.65%	-32.45%	267.04%	85.42%	364.52%	55.0%	-66.39%
% of Gross Profit
Research & Development	$48.90M	$69.98M	$0.00	$1.750M	$85.76M	$72.74M	$44.23M	$33.09M	$18.36M	$10.72M	$4.576M	$19.51M	$31.13M	$4.150M	$2.940M	$5.980M
YoY Change	-30.12%		-100.0%	-97.96%	17.89%	64.48%	33.64%	80.27%	71.3%	134.21%	-76.55%	-37.31%	650.12%	41.16%	-50.84%
% of Gross Profit
Depreciation & Amortization	$450.0K	$498.0K	$466.0K	$691.0K	$494.0K	$643.0K	$219.0K	$80.00K	$64.99K	$10.97K	$6.216K	$4.618K	$0.00	$10.00K	$10.00K	$0.00
YoY Change	-9.64%	6.87%	-32.56%	39.88%	-23.17%	193.61%	173.75%	23.1%	492.21%	76.54%	34.6%		-100.0%	0.0%
% of Gross Profit
Operating Expenses	$71.81M	$94.11M	$0.00	$1.750M	$118.7M	$107.5M	$61.25M	$33.09M	$18.36M	$10.72M	$4.576M	$19.51M	$34.00M	$4.770M	$3.340M	$7.160M
YoY Change	-23.7%		-100.0%	-98.53%	10.36%	75.59%	85.07%	80.27%	71.3%	134.21%	-76.55%	-42.61%	612.79%	42.81%	-53.35%
Operating Profit	-$64.65M	-$94.11M	-$132.7M		-$102.7M	-$92.74M	-$52.23M	-$45.28M	-$29.66M	-$23.96M	-$19.60M	-$24.86M
YoY Change	-31.31%	-29.07%			10.76%	77.56%	15.35%	52.68%	23.79%	22.2%	-21.12%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Interest Expense	$3.451M	$1.022M	$302.0K	$2.620M	$4.300M	$3.080M	$370.0K	$400.0K	$1.200M	$170.0K	$200.0K	$70.00K	-$340.0K	-$4.520M	-$1.200M	-$1.620M
YoY Change	237.67%	238.41%	-88.47%	-39.07%	39.61%	732.43%	-7.5%	-66.67%	605.88%	-15.0%	185.71%	-120.59%	-92.48%	276.67%	-25.93%
% of Operating Profit
Other Income/Expense, Net	$3.451M	$1.022M	$302.0K	$2.624M	$4.305M	$3.083M	$368.0K	$399.0K	$1.202M	$167.7K	$201.0K	$65.07K	$0.00	-$6.000M	$0.00
YoY Change	237.67%	238.41%	-88.49%	-39.05%	39.64%	737.77%	-7.77%	-66.8%	616.84%	-16.6%	208.95%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Pretax Income	-$61.20M	-$93.09M	-$132.4M	-$62.15M	-$98.41M	-$89.65M	-$51.86M	-$44.88M	-$28.45M	-$23.79M	-$39.01M	-$24.79M	-$34.34M	-$15.29M	-$4.540M	-$8.790M
YoY Change	-34.26%	-29.68%	113.0%	-36.84%	9.77%	72.88%	15.55%	57.73%	19.61%	-39.02%	57.36%	-27.81%	124.59%	236.78%	-48.35%
Income Tax	$33.00K	$0.00	-$2.500M	$0.00	-$774.0K	$1.099M	-$9.050M	-$618.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$61.23M	-$93.09M	-$129.9M	-$62.15M	-$97.63M	-$90.75M	-$42.81M	-$44.26M	-$28.45M	-$23.79M	-$19.40M	-$24.79M	-$34.34M	-$15.29M	-$4.539M	-$8.786M
YoY Change	-34.23%	-28.31%	108.93%	-36.34%	7.58%	111.99%	-3.28%	55.55%	19.61%	22.6%	-21.73%	-27.82%	124.61%	236.84%	-48.34%
Net Earnings / Revenue	-854.78%		-2076.35%	-78.56%	-611.63%	-613.02%	-85.62%
Basic Earnings Per Share	-$13.38	-$1.92	-$3.00
Diluted Earnings Per Share	-$13.38	-$1.92	-$3.000M	-$1.754M	-$3.718M	-$3.980M	-$2.412M	-$2.569M	-$1.812M	-$3.399M	-$10.05M	-$9.722M	-$17.89M	-$11.33M	-$3.363M	-$6.511M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Cash & Short-Term Investments	$130.2M	$91.61M	$146.6M	$216.4M	$274.0M	$218.1M	$119.9M	$53.00M	$67.70M	$29.10M	$27.10M	$20.50M	$37.00M	$14.60M	$100.0K	$0.00
YoY Change	42.18%	-37.52%	-32.24%	-21.02%	25.63%	81.9%	126.23%	-21.71%	132.65%	7.38%	32.2%	-44.59%	153.42%	14500.0%
Cash & Equivalents	$19.84M	$52.42M	$45.63M	$59.40M	$46.70M	$41.50M	$82.00M	$28.60M	$27.10M	$29.10M	$27.10M	$20.50M	$37.00M	$14.60M	$100.0K	$0.00
Short-Term Investments	$110.4M	$39.19M	$101.0M	$157.0M	$227.3M	$176.6M	$37.90M	$24.40M	$40.60M
Other Short-Term Assets	$3.497M	$4.413M	$7.241M	$6.900M	$5.400M	$2.000M	$900.0K	$600.0K	$700.0K	$100.0K	$100.0K	$100.0K	$100.0K	$0.00	$0.00	$800.0K
YoY Change	-20.76%	-39.06%	4.94%	27.78%	170.0%	122.22%	50.0%	-14.29%	600.0%	0.0%	0.0%	0.0%			-100.0%
Inventory
Prepaid Expenses
Receivables	$43.00K	$944.0K	$336.0K	$1.200M	$3.400M	$2.400M	$2.300M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$133.8M	$96.97M	$154.2M	$224.5M	$282.8M	$222.5M	$123.1M	$53.60M	$68.40M	$29.20M	$27.10M	$20.50M	$37.00M	$14.60M	$100.0K	$800.0K
YoY Change	37.97%	-37.12%	-31.31%	-20.62%	27.1%	80.75%	129.66%	-21.64%	134.25%	7.75%	32.2%	-44.59%	153.42%	14500.0%	-87.5%
Property, Plant & Equipment	$2.724M	$3.938M	$7.181M	$10.70M	$13.80M	$600.0K	$900.0K	$200.0K	$100.0K	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-30.83%	-45.16%	-32.89%	-22.46%	2200.0%	-33.33%	350.0%	100.0%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$27.97M				$3.700M	$2.700M	$23.60M	$100.0K	$0.00
YoY Change		-100.0%					37.04%	-88.56%	23500.0%
Other Assets	$312.0K	$889.0K	$1.703M	$6.400M	$1.700M	$3.300M							$0.00	$0.00	$100.0K	$0.00
YoY Change	-64.9%	-47.8%	-73.39%	276.47%	-48.48%									-100.0%
Total Long-Term Assets	$3.036M	$4.827M	$36.86M	$58.80M	$57.10M	$45.50M	$46.20M	$44.50M	$65.30M	$42.00M	$0.00	$100.0K	$0.00	$0.00	$100.0K	$100.0K
YoY Change	-37.1%	-86.9%	-37.32%	2.98%	25.49%	-1.52%	3.82%	-31.85%	55.48%		-100.0%			-100.0%	0.0%
Total Assets	$136.8M	$101.8M	$191.1M	$283.3M	$339.9M	$268.0M	$169.3M	$98.10M	$133.7M	$71.20M	$27.10M	$20.60M	$37.00M	$14.60M	$200.0K	$900.0K
YoY Change
Accounts Payable	$461.0K	$2.493M	$2.659M	$4.600M	$1.700M	$3.700M	$2.100M	$2.400M	$1.400M	$900.0K	$2.600M	$1.800M	$2.300M	$300.0K	$400.0K	$4.100M
YoY Change	-81.51%	-6.24%	-42.2%	170.59%	-54.05%	76.19%	-12.5%	71.43%	55.56%	-65.38%	44.44%	-21.74%	666.67%	-25.0%	-90.24%
Accrued Expenses	$7.849M	$13.80M	$13.41M	$19.80M	$16.30M	$9.700M	$6.100M	$4.800M	$2.000M	$100.0K	$0.00	$900.0K	$200.0K	$200.0K	$1.200M	$400.0K
YoY Change	-43.14%	2.9%	-32.25%	21.47%	68.04%	59.02%	27.08%	140.0%	1900.0%		-100.0%	350.0%	0.0%	-83.33%	200.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.200M	$300.0K	$200.0K
YoY Change													-100.0%	300.0%	50.0%
Long-Term Debt Due														$0.00	$7.500M	$0.00
YoY Change														-100.0%
Total Short-Term Liabilities	$39.23M	$16.30M	$16.07M	$24.40M	$24.40M	$18.50M	$13.50M	$7.100M	$3.400M	$1.100M	$2.600M	$2.700M	$2.500M	$1.700M	$12.40M	$4.700M
YoY Change	140.7%	1.39%	-34.13%	0.0%	31.89%	37.04%	90.14%	108.82%	209.09%	-57.69%	-3.7%	8.0%	47.06%	-86.29%	163.83%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.300M	$1.200M	$5.600M
YoY Change													-100.0%	8.33%	-78.57%
Other Long-Term Liabilities	$56.50M	$2.834M	$6.058M	$15.70M	$39.70M	$35.70M	$40.60M					$0.00
YoY Change	1893.68%	-53.22%	-61.41%	-60.45%	11.2%	-12.07%
Total Long-Term Liabilities	$56.50M	$2.834M	$6.058M	$15.70M	$39.70M	$35.70M	$40.60M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.300M	$1.200M	$5.600M
YoY Change	1893.68%	-53.22%	-61.41%	-60.45%	11.2%	-12.07%							-100.0%	8.33%	-78.57%
Total Liabilities	$95.73M	$19.13M	$22.13M	$42.70M	$66.70M	$57.40M	$56.20M	$18.20M	$15.00M	$12.70M	$2.600M	$2.700M	$2.500M	$3.000M	$13.50M	$10.30M
YoY Change	400.4%	-13.56%	-48.17%	-35.98%	16.2%	2.14%	208.79%	21.33%	18.11%	388.46%	-3.7%	8.0%	-16.67%	-77.78%	31.07%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	4.577M	48.41M	43.28M
Diluted Shares Outstanding	4.577M	48.41M	43.28M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $115.3 Million

About Assembly Biosciences Inc

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 65 full-time employees. The company went IPO on 2010-12-17. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Industry: Pharmaceutical Preparations Peers: aTyr Pharma Inc Gelesis Holdings Inc Surrozen Inc Fortress Biotech Inc Cue Biopharma Inc Finch Therapeutics Group Inc HOOKIPA Pharma Inc NextCure Inc Xilio Therapeutics Inc